
By Blake Brittain
Jan 6 (Reuters) - Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a Bayer spokesperson confirmed.
The patent infringement lawsuits said the companies copied technology developed by Monsanto in the 1980s for strengthening mRNA in crops in order to stabilize the genetic material used in their vaccines.
Bayer separately filed a similar lawsuit against Johnson & Johnson in New Jersey federal court on Tuesday, arguing that a DNA-based process J&J used in manufacturing its shots infringed the patent.
Bayer's complaints add to a web of patent lawsuits over the blockbuster COVID shots, which include an ongoing lawsuit filed by Moderna against Pfizer in 2022.
Bayer was not involved in developing COVID vaccines and does not make or sell any version of them. It asked the courts for an unspecified amount of monetary damages and said it was not seeking to block the companies from manufacturing their vaccines.
Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty in 2024, while Moderna earned $3.2 billion from its Spikevax, according to company reports, a fraction of their sales at the height of the pandemic.
Johnson & Johnson stopped selling its COVID vaccine in the United States in 2023.
Bayer's lawsuits said Monsanto scientists pioneered technology in the 1980s for reducing mRNA instability to make more pest-resistant crops. Bayer alleged that Pfizer and Moderna utilized technology for improving the stability of mRNA that infringes one of its patents.
(Reporting by Blake Brittain in WashingtonEditing by Bill Berkrot)
LATEST POSTS
- 1
IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses - 2
Undeniably popular Historical centers: Where Craftsmanship and History Meet - 3
DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit - 4
Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market - 5
From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime
Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
The 3 little words TV fans can't stop obsessing over
CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
US FDA unveils new pathway to approve personalized therapies
Careful Connections: Building Association and Trust
Former elite Australian soldier charged with Afghan war crimes
This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
A Couple of Modest Guitars for 2024












